AmerisourceBergen Approves Quarterly Dividend

Mon Feb 4, 2013 12:31pm EST

* Reuters is not responsible for the content in this press release.

VALLEY FORGE, Pa.--(Business Wire)--
The Board of Directors of AmerisourceBergen Corporation (NYSE: ABC) today
declared a cash dividend of $0.21 per share on Common Stock, payable March 4,
2013, to stockholders of record at the close of business on February 15, 2013. 

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in the
pharmaceutical supply channel, the Company provides drug distribution and
related services designed to reduce costs and improve patient outcomes.
AmerisourceBergen's service solutions range from niche premium logistics and
pharmaceutical packaging to reimbursement and pharmaceutical consulting
services. With over $80 billion in annualized revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 14,500 people.
AmerisourceBergen is ranked #29 on the Fortune 500 list. For more information,
go to 

Forward-Looking Statements

Certain of the statements contained in this press release are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These statements are based
on management's current expectations and are subject to uncertainty and change
in circumstances. Among the factors that could cause actual results to differ
materially from those projected, anticipated or implied are the following:
changes in pharmaceutical market growth rates; the loss of one or more key
customer or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or insolvencies;
changes in pharmaceutical manufacturers' pricing and distribution policies or
practices; adverse resolution of any contract or other dispute with customers or
suppliers; federal and state government enforcement initiatives to detect and
prevent suspicious orders of controlled substances and the diversion of
controlled substances; qui tam litigation for alleged violations of fraud and
abuse laws and regulations and/or any other laws and regulations governing the
marketing, sale, purchase, and/or dispensing of pharmaceutical products or
services and any related litigation, including shareholder derivative lawsuits;
changes in federal and state legislation or regulatory action affecting
pharmaceutical product pricing or reimbursement policies, including under
Medicaid and Medicare; changes in regulatory or clinical medical guidelines
and/or labeling for the pharmaceutical products we distribute, including certain
anemia products; price inflation in branded pharmaceuticals and price deflation
in generics; greater or less than anticipated benefit from launches of the
generic versions of previously patented pharmaceutical products; significant
breakdown or interruption of our information technology systems; our inability
to realize the anticipated benefits of the implementation of an enterprise
resource planning (ERP) system; success of integration, restructuring or systems
initiatives; interest rate and foreign currency exchange rate fluctuations;
risks associated with international business operations, including
non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws
and economic sanctions and import laws and regulations; economic, business,
competitive and/or regulatory developments outside of the United States; changes
and/or potential changes in Canadian provincial legislation affecting
pharmaceutical product pricing or service fees or regulatory action by
provincial authorities in Canada to lower pharmaceutical product pricing and
service fees; the impact of divestitures or the acquisition of businesses that
do not perform as we expect or that are difficult for us to integrate or
control; our inability to successfully complete any other transaction that we
may wish to pursue from time to time; changes in tax laws or legislative
initiatives that could adversely affect our tax positions and/or our tax
liabilities or adverse resolution of challenges to our tax positions; increased
costs of maintaining, or reductions in our ability to maintain, adequate
liquidity and financing sources; volatility and deterioration of the capital and
credit markets; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors affecting our business generally. Certain
additional factors that management believes could cause actual outcomes and
results to differ materially from those described in forward-looking statements
are set forth (i) in Item 1A (Risk Factors) in the Company's Annual Report on
Form 10-K for the fiscal year ended September 30, 2012 and elsewhere in that
report and (ii) in other reports filed by the Company pursuant to the Securities
Exchange Act of 1934.

AmerisourceBergen Corporation
Barbara Brungess, 610-727-7199

Copyright Business Wire 2013